Marbofloxacin

Marbofloxacin

SCHEMBL134860

CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2OCN4C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 1.00
ALDH1A1 P00352 6/20 0.67
HPGD P15428 4/20 0.67
HSD17B10 Q99714 3/20 0.67
ALB P02768 1/20 0.67
HRH3 Q9Y5N1 1/20 0.67
TUBB4A P04350 1/20 0.66
POLB P06746 1/20 0.66
TUBB P07437 1/20 0.66
TUBA3C P0DPH7 1/20 0.66
TUBA1B P68363 1/20 0.66
TUBA4A P68366 1/20 0.66
TUBB4B P68371 1/20 0.66
TUBB3 Q13509 1/20 0.66
TUBB2A Q13885 1/20 0.66
TUBB8 Q3ZCM7 1/20 0.66
TUBA3E Q6PEY2 1/20 0.66
TUBA1A Q71U36 1/20 0.66
SLC47A1 Q96FL8 1/20 0.66
TUBA1C Q9BQE3 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Marbofloxacin SCHEMBL29355042 1.00 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10ALB
Marbofloxacin SCHEMBL10563057 0.99 KDM4E (0.98) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL12637996 0.97 KDM4E (0.94) KDM4EALDH1A1HPGDHSD17B10ALB
Marbofloxacin SCHEMBL1768472 0.96 KDM4E (0.93) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL16518628 0.92 KDM4E (0.85) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL9533526 0.91 KDM4E (0.84) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL12665530 0.91 KDM4E (0.84) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL9533821 0.91 KDM4E (0.83) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL10700294 0.90 KDM4E (0.82) KDM4EALDH1A1HPGDHSD17B10ALB
SCHEMBL10561493 0.90 KDM4E (0.82) KDM4EALDH1A1HPGDHSD17B10ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3446 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079888-A Marbofloxacin intermediate 2026-05-26 CN claimed
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20260060990-A1 OTIC FORMULATIONS, METHODS AND DEVICES DECHRA VETERINARY PRODUCTS LLC (US) 2026-03-05 US claimed
US-12491189-B2 OTIC formulations, methods and devices DECHRA VETERINARY PRODUCTS, LLC (US) 2025-12-09 US claimed
US-12480089-B2 Antiviral treatment comprising Blis containing probiotic products BLIS TECHNOLOGIES LIMITED (NL) 2025-11-25 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
US-6114351-A N-oxides as antibacterial agents BAYER AKTIENGESELLSCHAFT (DE) 2000-09-05 US claimed
CN-1209065-A Otic microbial combinations BAYER AG (US) 1999-02-24 CN claimed
EP-0869795-A1 OTIC MICROBIAL COMBINATIONS Bayer Corporation (US) 1998-10-14 EP claimed
CN-1190958-A Novel antimicrobial compositions BAYER AG (DE) 1998-08-19 CN claimed
US-5756506-A ADMINISTERING TO ANIMALS IN TREATMENT OF BACTERIAL INFECTIONS BAYER CORPORATION (US) 1998-05-26 US claimed
EP-0828715-A1 N-OXIDES AS ANTIBACTERIAL AGENTS BAYER AG (DE) 1998-03-18 EP claimed
WO-1997024128-A1 OTIC MICROBIAL COMBINATIONS BAYER CORPORATION (US) 1997-07-10 WO claimed
WO-1996038417-A1 N-OXIDES AS ANTIBACTERIAL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1996-12-05 WO claimed
EP-0259804-B1 Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process HOFFMANN LA ROCHE (CH) 1993-11-18 EP claimed
EP-0259804-A2 Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process F. HOFFMANN-LA ROCHE AG (CH) 1988-03-16 EP claimed